Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Home-Grown Oral COVID Antiviral Eyes Wider Population

Simcere Kicks Off Phase I

Executive Summary

Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.

You may also be interested in...



Homegrown China Oral Antiviral Shows Early Promise

Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.

Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron

While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.

Chinese Biotech Bets On Intravenous 3CL Antiviral Contender For COVID-19

While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel